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INTRODUCTION 
Analytical chemistry is measurement science consisting of a set of powerful ideas 
and methods that are useful in all fields of science and method. it is used to study the 
chemical composition, structure and behavior of compounds. The purpose of 
chemical analysis is together and interpret chemical information that will be the 
value of society in a wide range of contexts. involves the application of a range of 
techniques and methodologies to obtain and assess qualitative, quantitative and 
structural information on the nature of components.[1,2] 
Qualitative analysis is the identification of elements and compounds present in a 
sample. Quantitative analysis is the determination of the absolute or relative 
amounts of elements or compounds present in a sample. 
Structural analysis is the determination of the special arrangement of atoms in an 
element or molecule or the identification of characteristic groups or atoms. 
A typical quantitative analysis[2] involves the sequence of steps shown in the 
following flow diagram (figure-1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Select method 
Acquire sample 
Process sample 
Change 
Chemical 
form 
Is Sample soluble 
Carry out 
chemical 
dissolution 
Measurable property  
Eliminate interferences 
Measure property 
Calculate result 
Evaluating results by 
estimating their reliability 
No  No  
Yes 
Yes 
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High Performance Liquid Chromatography [ 3,4,5,6,7] 
High performance liquid chromatography is the fastest growing analytical technique 
for the analysis of the drugs. Its simplicity, high specificity and wide range of 
sensitivity make it ideal for an analysis of many drugs in both dosage forms and 
biological fluids. HPLC was developed in the late 1960s and 1970s. Today it is 
widely accepted separation technique for both sample analysis and purification in 
variety of areas.  
Guide to Liquid Chromatography Mode Selection 
Selection of chromatography mode is based upon the analyte polarity, solubility and 
ionic nature. [7] A guide to liquid chromatography mode selection is represented in 
figure-2 
Figure - 2 Guide to Liquid Chromatography Mode Selection Reverse Phase 
HPLC 
 
   
MW<2000  
 
 
  
 
 
 
MW>2000 
 
Reverse phase, aqueous mobile 
phase Non-ionic 
High polarity Liquid, solid or bonded phase 
Acidic Anion exchange/ion pair 
ionic 
Sample Basic 
Cation exchange/ion pair 
Water soluble 
Size exclusion, aqueous mobile 
phase 
Water insoluble Size exclusion, non-aqueous mobile 
phase. 
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Figure - 3 Block diagram showing the components of an HPLC instrument 
 
 
 
F 
Reverse phase column packing 
The liquid-liquid partition chromatography uses a stationary phase consisting of 
liquid layer adsorbed to a surface of silica or alumina. In case of bonded phase or 
reverse phase HPLC uses a stationary phase consisting of an organic moiety 
chemically bonded to the surface of silica through the surface silanol groups. Since 
the organic moieties are generally long-chain hydrocarbons, the mobile phases are 
generally polar. In this mode, the more polar solutes are eluted first while the non-
polar compounds are eluted later. The silanol group can react with a chlorosilane 
group to form the popular (ODS & C18) octadecylsilane packing. 
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E.g. Octadecylsilane (ODS or C18).  
  CH3         CH3  
  
    
 
Si     OH  + Cl  –   Si  – (CH2)17 – CH3               Si – O – Si – (CH2)17 – CH3 
+HCl 
        
 
  CH3         CH3   
For silica based bonded materials, the suitable working pH range is 2 - 8. At pH 
values of less than 2, the Si-C bond is attached and at the higher pH values, 
hydrolysis of the siloxane takes place which leads to degradation or destruction of 
the packing. In most of the applications of RP-HPLC, elution is carried out with 
highly polar solvents such as methanol, acetonitrile or tetrahydrofuran in various 
concentrations. [8] 
Reverse phase mobile phase 
The primary constituent of RP-HPLC mobile phase is water. Water miscible 
solvents such as methanol, ethanol, acetonitrile, dioxane, tetrahydrofuran and 
dimethyl formamide are added to adjust the polarity of the mobile phase. 
Additionally acids, bases, buffers and/or ionic surfactants are added. The water 
should be of high quality, either distilled or demineralised water. 
The most widely used organic modifiers are methanol, acetonitrile and 
tetrahydrofuran. Methanol and acetonitrile have comparable polarities but 
acetonitrile is an aprotic solvent. Ethanol, 1-propanol and 2-propanol are also useful 
but less polar than methanol. Dioxane, tetrahydrofuran are aprotic solvents that are 
less polar than acetonitrile. Reverse phase mobile phases are generally non-
flammable due to high water content. Degassing is quite important with reverse 
phase mobile phases.[8]  
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ANALYTICALMETHOD DEVELOPMENT [1,9] 
Establishing an accurate assay procedure for each ingredient of complex dosage 
formulation containing several therapeutically and chemically compatible drugs with 
very similar chemical nature is a critical process. The presence of excipients, 
additives and decomposition products further complicates the analysis. Therefore 
analytical development is done for few drugs where no compendial method is 
available. 
 
Method development is done for: 
 New drug products 
 Already existing products 
Methods are developed for new products when no official methods are available and 
for already existing products to reduce the cost and time for better precision and 
ruggedness. 
 
STEPS OF METHOD DEVELOPMENT1 
It starts with the documentation of the developed studies. All the data related to 
these studies are established and recorded in laboratory notebook. 
 
1.  ANALYTICAL STANDARD CHARACTERIZATION 
All the known information about the drug or analyte and its structure is collected 
such as its physical and chemical properties, toxicity, purity, hygroscopic nature 
solubility and stability. 
a. The standard analyte is obtained. Necessary arrangement is made for proper 
storage in refrigerator, desiccators and freezer. 
b. When multiple components are to be analyzed in the sample matrix the 
number of components  are  noted, data is assembled and the availability of 
standards for each one is determined. 
c. Special attention to be taken when sample is in less quality. 
d. Only the methods which are compatible with sample stability are considered. 
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2.  METHOD REQUIREMENTS 
The objectives of method are defined. The required detection limits, linearity, range, 
accuracy and precision are defined. 
3.  LITERATURE SEARCH AND RESEARCH METHODOLOGY 
 Carry out the literature survey for all types of information to the analyte. Literature 
is done for synthesis, physico-chemical properties, solubility and relevant analytical 
methods. Books, periodicals, chemical manufacturers and regulatory agency 
compendia such as USP/NF, AOAC publications are reviewed along with chemical 
abstract service (CAS) automated computerized literature searches. 
a. If any reported methods from the literature are adaptable to the current 
laboratory setting and future needs are determined. 
b. Using information in the literature and prints, methodology is adapted. The 
methods are modified wherever necessary; acquire additional existing 
methods for in house analytes and samples. 
c. If there are no prior methods for the analytes in the literature, the compounds 
that are similar and chemical properties are investigated and are worked out. 
 
4.  INSTRUMENTAL SET UP AND INITIAL STUDIES 
a. The required instrument is set up. Installation, operational and performance 
of instrumentation using laboratory standard operating procedure are 
reviewed. 
b. Always new consumables (solvents, filter and gases) are used. 
c. The analyte standard in a suitable injection/introduction solution and in 
known concentration and solvents are prepared. It is important to start with 
an authentic, known standard rather than with a complex sample matrix. If 
the sample is extremely close to the standard (example: bulk drug) then it is 
possible to start work with the actual sample. 
d. Feasibility of method with regards to the analytical figures of merit obtained 
is evaluated. 
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5.  OPTIMIZATION 
During optimization one parameter is changed at a time and set of conditions are 
isolated rather than using a trial and error approach. Work has been done from an 
organized methodological plan and every step is documented in case of dead ends. 
 
 
6.  DOCUMENTATION OF METHOD DEVELOPMENT WITH ACTUAL  
     SAMPLE 
The sample solution should lead to absolute identification of the peak of interest 
apart from all other matrix components. 
7. EVALUATION OF METHOD DEVELOPMENT WITH ACTUAL    
    SAMPLE 
The sample solution should lead to absolute identification of the peak of interest 
apart from all other matrix components. 
 
8.   DETERMINATION OF PERCENT RECOVERY OF ACTUAL SAMPLE  
     AND DEMONSTRATION OF QUANTITATIVE SAMPLE ANALYSIS. 
 Percentage recovery was determined by adding authentic standard analyte into a 
sample matrix. Reproducibility of recovery from sample to sample and  has been 
determined. It is not necessary to obtain 100% recovery as long as the results are 
reproducible and known with high degree of certainty. 
 
9.   ANALYTICAL METHOD VALIDATION [10, 11, 12, 13, 35, 36] 
Validation is a key process for effective Quality Assurance "Validation is 
establishing documented evidence which provides a high degree of assurance that a 
specific process or equipment will consistently produce a product or result meeting 
its predetermined specifications and quality attributes. 
The validation guidelines recommended from ICH (International Conference on 
Harmonization) consists characteristics for consideration during the validation of 
analytical procedures included as part of registration applications within EC, Japan 
and USA. 
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9.1 Type of analytical procedures to be validated 
Validation of analytical procedures is directed to the four most common types of 
analytical procedures. 
1. Identification test. 
2. Quantitative test for impurities content. 
3. Limit test for the control of impurities 
4. Quantitative test of the active moiety in samples of drug substance on drug 
product on other selected components in the drug product. 
Assay procedures are intended to measure the analyte present in given sample, assay 
represent a quantitative measurement of the major component(s) in the drug sample. 
 
9.2  Objective of validation [14, 15] 
The primary objective of validation is to form a basis for written procedure for 
production and process control which are designed to assure that the drug products 
have the identity, strength, quality, purity, safety and efficacy.  Each step of the 
manufacturing process must be controlled to maximize the probability that the 
finished products meet all quality and design specification. 
 
9.3  Benefits of Validation: 
a. Produces quality products. 
b. Helps in process improvement technology transfer, related product 
validation, failure investigation, and increased employee awareness. 
c. Cost reduction by increasing efficacy, few reject, longer equipment life, 
production of cost effective products. 
d. Helps in optimization of process or method. 
e. Regulatory affairs department approved the products for export. 
 
10.0 VALIDATION AS DEFINED BY DIFFERENT AGENCIES 
1. USFDA:  
According to this "Validation is the process of establishing documented evidence 
which provides a high degree of assurance that a specific process will consistently 
produce a product meeting its predetermined specifications and quality attributes. 
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2. WHO: 
Defines Validation as an action of providing any procedure, process, equipment, 
material, activity or system actually leads to the expected results. 
 
3.   EUROPEAN COMMITTEE:  
Defines Validation as an action of providing in accordance with the principles of 
GMP that any procedure, process, material, activity or system actually lead to 
expected results. This process consists of establishment of the performance 
characteristics and the limitations of the method. 
 
11.0  Method performance parameters are determined using equipment that is: 
1. Within specification. 
2. Working correctly. 
3. Adequately calibrated. 
12.0  Method validation is required when: 
1. A new method is developed. 
2. Revision of established method. 
3. When established methods are used in different laboratories and by 
different analysts. 
4. Comparison of methods. 
5. When quality control indicates method changes. 
 
13.0 Typical analytical parameters used in assay validation include: 
13.1 Precision  
13.2 Accuracy  
13.3 Linearity  
13.4 Range  
13.5 Ruggedness  
13.6 Robustness 
13.7 Limit  of  detection  
13.8 Limit  of  quantitation  
13.9 Selectivity  
13.10 Specificity  
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13.1 PRECISION  
The precision of an analytical procedure expresses the closeness of agreement 
between a series of measurement obtained from multiple sampling of the same 
homogenous sample under the prescribed conditions. Precision of an analytical 
procedure is usually expressed at the variance, standard deviation or coefficient of 
variation of a series of measurements.   
 
 Validation of tests for assay and for quantitative determination of impurities 
includes an investigation of precision. 
Precisionisdeterminedbyusingthemethodtoassayasampleforasufficientnumberof 
times to obtain statistically valid results (i.ebetween6-10). 
                                                                     STDdevx100% 
%RSD = 
          Mean 
 
13.2 REPEATABILITY 
It express the precision under the same operating conditions over a short interval of 
time.  Repeatability is also termed as intra - assay precision. It should be assessed 
using a minimum of nine determinations covering the specified range for the 
procedure (e.g. three concentration/three replicates each) or a minimum of 
determinations at 100% of the test concentration. 
13.3 INTERMEDIATE PRECISION 
The extent to which intermediate precision should be established depends on the 
circumstances under which the procedure is intended to be used.  The applicant 
should establish the effects of random events on the precision of the analytical 
procedure. Typical variations to be studied include days, analysts, equipment, etc. 
13.4 REPRODUCIBILITY 
  Reproducibility is assessed by means of an inter-laboratory trial.  Reproducibility 
should be    considered in case of the standardization of an analytical procedure, for 
instance inclusion of procedures in Pharmacopoeias.   
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13.5 ACCURACY 
 "Accuracy is a measure of the closeness of test results obtained by a method to the 
true value."  
 
  Accuracy indicates the deviation between the mean value found and the true value. 
It is determined by applying the method to samples to which known amounts of 
analyte have been added. These should be analyzed against standard and blank 
solutions to ensure that no interference exists. The accuracy is then calculated from 
the test results as a percentage of the analyte recovered by the assay. Accuracy and 
precision are not the same, as the diagram below indicates. A method can have good 
precision and yet not be accurate. 
 
 
 
 
 
 
 
                                                            Figure-4 
Errors in measurement can be divided into two general categories: systematic errors 
and random errors. 
Systematic errors result from sources that can be traced to the methodology, the 
instrument or the operator and affect both the accuracy and the precision of the 
measurement. 
Random errors only affect the precision and are difficult to eliminate, because they 
are the result of random fluctuations in the measured signal, due to noise and other 
factors. 
Whilst systematic errors are proportional to the sum of individual contributions, 
random errors are proportional to the root of the sum of the squares of the individual 
contributions. Thus, the imprecision of the entire procedure is often dominated by 
the random errors of the most imprecise step. 
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13.6 LINEARITY 
This is the method's ability to obtain results which are either directly, or after 
mathematical transformation proportional to the concentration of the analyte within 
a given range. Linearity is determined by calculating the regression line using a 
mathematical treatment of the results (i.e. least mean squares) vs. analyte 
concentration. 
 
 
 
13.7  RANGE 
The range of the method is the interval between the upper and lower levels of an 
analyte that have been determined with acceptable precision, accuracy and linearity. 
It is determined on either a linear or nonlinear response curve (i.e. where more than 
one range is involved, as shown below) and is normally expressed in the same units 
as the test results. 
 
 
 
 
 
 
 
 
Figure- 5 
 
13.8 RUGGEDNESS 
Ruggedness is the degree of reproducibility of results obtained by the analysis of the 
same sample under a variety of normal test conditions i.e. different analysts, 
laboratories, instruments, reagents, assay temperatures, small variations in mobile 
phase, different days etc. (i.e. from laboratory to laboratory, from analyst to analyst.) 
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13.9 ROBUSTNESS 
Robustness is depends on the type of procedure under study. It should show the 
reliability of an analysis with respect to deliberate variations in method parameters. 
It is the measure of capacity of an assay to remain by small but deliberate variations 
in method parameters and provide an indication of its reliability in normal usage 
degradation and variation in chromatography column, mobile phases and inadequate 
method development are common causes of lack of robustness. 
Examples of typical variations are 
 Stability of analytical solutions 
 Extraction time 
 Influence of variation of pH in a mobile phase 
 Influence of variation in mobile phase composition 
 Different columns 
 Temperatures 
 Flow rate 
 
13.10 LIMIT OF DETECTION 
This is the lowest concentration in a sample that can be detected, but not necessarily 
quantitated, under the stated experimental conditions. The limit of detection is 
important for impurity tests and the assays of dosages containing low drug levels 
and placebos. 
The limit of detection is generally quoted as the concentration yielding a signal-to-
noise ratio of 2:1 and is confirmed by analyzing a number of samples near this value 
(6) using the following equation. The signal-to-noise ratio (5) is determined by: 
s = H/h 
Where  H  =  height  of  the  peak  corresponding  to  the  component 
             h = absolute value of the largest noise fluctuation from the baseline of the 
chromatogram of a blank solution. 
Since  the  limit  of  detection  is  dependent  on  the  signal-to-noise  ratio,  it can  be  
improved  by  enhancing  the  analyte  signal  and  reducing  the  detector  noise. The 
signal (i.e. peak height) can be increased by selecting the optimum monitoring 
wavelength, increasing the injection volume or mass (below signal or column 
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saturation), increasing the peak sharpness with high efficiency columns and by 
optimizing the mobile phase. For absorbance detectors, longer path lengths in the 
flow cell enhance sensitivity though often to the detriment of post column 
dispersion. 
 Noise can be reduced by using high sensitivity detectors with low noise and drift 
characteristics, slower detector response time, mobile phases with low absorbance 
and pumps with low pulsation. 
 
 
13.11 LIMIT OF QUANTITATION 
This is the lowest concentration of analyte in a sample that can be determined with 
acceptable precision and accuracy. 
It is quoted as the concentration yielding a signal-to-noise ratio of 1 0: 1 and is 
confirmed by analyzing a number of samples near this value. 
13.12 SELECTIVITY AND SPECIFICITY 
Selectivity is the ability to measure accurately and specifically the analyte in the 
presence of components that may be expected to be present in the sample matrix. 
Specificity for an assay ensures that the signal measured comes from the substance 
of interest and that there is no interference from excipients and/or degradation 
products and/or impurities. 
Determination  of  this  can  be  carried  out  by  assessing  the  peak  identity  and  
purity. 
Diode array detectors can facilitate the development and validation of HPLC assays. 
Spectral data obtained from diode array detectors, effectively supplement the 
retention time data for peak identification, also spectral manipulation often provides 
information about the peak purity. The table below lists several of the techniques 
available for assessing peak identity and purity. 
The purity index is a measure of the peak's relative purity, measured using a full 
comparison of spectral data for the leading and training edge of the peak Figure 4. A 
value of 1.5 is commonly accepted to indicate a pure peak but >1.5 would indicate 
the presence of an impurity, (9) as shown in Figure 6 & 7. 
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Figure- 6 
Spectral comparison showing peak purity 
 
 
Comparison of reference versus sample apex spectra for peak 
identity 
 
 
Figure-7 
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14.0 SYSTEM SUITABILITY TESTS (SST) 
Once a method or system has been validated the task becomes one of routinely 
checking the suitability of the system to perform within the validated limits. 
 The simplest form of an HPLC system suitability test involves a comparison of the 
chromatogram trace with a standard trace. This allows a comparison of the peak 
shape, peak width, and baseline resolution. 
Alternatively these parameters can be calculated experimentally to provide a 
quantitative system suitability test report: 
14.1 Number of theoretical plates (efficiency) 
14.2 Capacity factor 
14.3 Separation (relative retention) 
14.4 Resolution 
14.5 Tailing factor 
14.6 Relative Standard Deviation (Precision) 
These  are  measured  on  a  peak  or  peaks  of  known  retention  time  and  peak  
width. 
15.0 PLATE NUMBER OR NUMBER OF THEORETICAL PLATES (N) 
This measures the sharpness of the peaks and therefore the efficiency of the column. 
This can be calculated in various ways, for example the USP uses the peak width at 
the base and the BP at half the Height. 
An equation used to calculate ‘N’ is 
N = 5.54[t/wh/2]2 
Where 
Wh/2 = peak width at 1/2 peak height Wb = peak width at base 
t  =   retention time of peak 
 
 
 
 
 
 
Figure- 8 
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Therefore  the  higher  the  plate  number  the  more  efficient  the  column. 
The plate number depends on column length - i.e. the longer the column the larger 
the plate number. Therefore the column's efficiency can also be quoted as: 
Either-  as  the  plate  height  (h), or the  height  equivalent  to  one  theoretical  plate  
(HETP). 
h= L/n 
      Where L = length of column n 
       Or - as plates/meter. 
16.0 CAPACITY FACTOR  (CAPACITY  RATIO)  K 
This value gives an indication of how long each component is retained on the 
column (i.e. how many times longer the component is retarded by the stationary 
phase than it spends in the mobile phase). 
 
 
 
 
 
 
 
 
Figure- 9 
k' is used in preference to retention time because it is less sensitive to fluctuations in 
chromatographic conditions (i.e. flow rate) and therefore ensures greater 
reproducibility from run to run. In practice the k value for the first peak of interest 
should be >l to assure that it is separated from the solvent. 
17.0 SEPARATION FACTOR (RELATIVE RETENTION) 
This describes the relative position of two adjacent peaks. Ideally, it is calculated 
using the capacity factor because the peaks' separation depends on the components' 
interaction with the stationary phase. 
Therefore considering peaks A and B 
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Figure- 10 
 
k  for  the  later  peak  is  always  placed  in  the  numerator  to  assure  a  value  >l. 
If  the  capacity factor  is  used  then  the  separation  factor  should  be  consistent  
for  a  given column, mobile phase, composition and specified temperature, 
regardless of the instrument used. 
18.0 PEAK RESOLUTION  R 
  This is not only a measure of the separation between two peaks, but also the 
efficiency of the column. It is expressed as the ratio of the distance between the two 
peak maxima. (At) to the mean value of the peak width at base (Wb). 
 
 
 
 
 
 
 
 
 
Figure- 11 
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19.0 TAILING FACTOR  T 
This is a measure for the asymmetry of the peak. 
 
 
 
 
 
 
 
 
Figure- 12 
20.0 RELATIVE STANDARD  DEVIATION  OR  PRECISION 
For an HPLC system this would involve the reproducibility of a number of replicate 
injections (i.e. 6) of an analytical solution. 
The USP requires that unless otherwise specified by a method: 
if a relative standard deviation of <2% is required then five replicate injections 
should be used. if a relative standard deviation of >2% is required then six replicate 
injections should be used Factors  which  could  affect  the  precision  of  an  HPLC  
system are shown in table 1. 
Table No. 1   
                                                 
 
Precision Controlling  Factors 
Retention  time 
Pump  flow and  composition  precision  Column  temperature 
Mobile  phase  composition 
Peak  area 
Auto sampler:  inj  mode,  inj  volume  
Pump:  flow, pulsation  
Detector:  noise  and  drift,  response 
 Data  system:  sampling  rate, integration  parameters 
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In most cases the system's Relative Standard Deviation is required; deciding which 
of the other tests are required is not straightforward. To assist with the decision it 
has been suggested that those parameters which have an effect on the system 
precision should be used. For instance the resolution of two peaks with similar 
retention times should be quoted, because, if it is below a critical value, the precision 
will be affected. 
In addition "diode array" detectors allow for the determination of the relative purity 
factor typically called: Peak Purity. 
The retention time precision is important, because not only is retention time the 
primary method for peak identification, but also variations can indicate problems 
within the LC system (i.e. with the piston seals, check valves etc). Use of a column 
oven can overcome laboratory temperature variations, which is the most common 
cause of retention time drift. 
The most dominant factor controlling the repeatability of peak area is the auto 
sampler’s precision, though the effect of noise and integration parameters will 
become more significant with small peaks 
 
21.0 METHODS USED FOR THE EXAMINATION OF              
      PHARMACEUTICAL MATERIAL MAY BE BROADLY       
      CLASSIFIED AS: 
CLASS A: Tests designed to establish identity, whether of bulk drug substances 
or of a particular ingredient in a finished dosage form. 
CLASS B: Methods designed to detect and quantitate impurities in a bulk drug 
substance or finished dosage form. 
CLASS C: Methods used to determine quantitatively the concentration of a bulk 
drug substance or of a major ingredient in a finished dosage form, 
CLASS D: Methods used to assess the characteristics of finished dosage forms 
such as dissolution profile and content uniformity. 
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LITERATURE REVIEW 
Systematic literature survey is the main basis for the planning of any scientific work 
and due to the same reasons here the review of literature regarding estimation of 
Nalbuphine HCl in Tablet dosage formulation. 
1. Khalid A. Attia  et al., have reported “A simple, sensitive, stability-indicating 
HPLC method was developed and validated for the quantitative 
determination of nalbuphine hydrochloride in presence of its degradation 
product.The analysis was carried out on a BDS Hypersil C18 ( 250 X 4.6 X 
5µm particle size) using a mobile phase consisting of 5 mM sodium acetate 
buffer; pH 5.5: acetonitrile (40:60, v/v). The analysis was performed at 
ambient temperature with a flow rate of 1 ml/min and UV detection at 210 
nm. The method showed good linearity over the concentration range of 1-15 
µg/ml with a lower detection limit of 0.243 and quantification limit of 0.737 
µg/ml. The proposed method can selectively analyse the drug in presence of 
up to 87% of its oxidative degradate with mean recovery± RSD% of 
100.08±0.678.The method was validated and successfully applied for 
determination of nalbuphine in its commercial preparation and the obtained 
results were statistically compared with those of the reported method by 
applying t-test and F-test at 95% confidence level and no significant 
difference was observed regarding accuracy and precision.. 
2. Mary Ann Quarry et.al., A stability-indicating liquid chromatographic 
method has been developed for the determination of nalbuphine 
hydrochloride, 
methylparaben, and propylparaben in nalbuphine hydrochloride injection. 
Reversed-phase chromatography was carried out using 
a mobile phase containing 0.05 % trifuoroacetic acid, acetonitrile, and 
tetrahydrofuran. Quantitation was achieved with UV 
detection at 280 nm. Validation data for linearity, accuracy, precision, 
specificity, and robustness are presented. The chromatographic 
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system resolves nalbuphine from synthetic impurities and degradation 
products. 
3. Mary Ann Quarry et alA method for the Determination of impurities and 
degradation products in nalbuphine hydrochloride injection by gradient 
elution high performance liquid chromatography (HPLC) is reported. 
Reversed phase gradient elution chromatography was carried out using a 
mobile phase containing 0.05% trifluoroacetic acid, acetonitrile, and 
tetrahydrofuran. Validation data for linearity, accuracy, precision, robustness, 
detection limit, and quantitation limit are presented. The chromatographic 
system resolves nalbuphine from related substances with corrections made 
for differences in detector response at the specified wavelength. 
4. Louise M. Dubé, Nicole Beaudoin et al., A rapid, selective and reproducible 
high-performance liquid chromatographic assay with electrochemical 
detection was developed for the determination of nalbuphine in human 
plasma. The method involves extraction with chloroform—isopropanol at pH 
9.4, back-extraction into dilute phosphoric acid and reversed-phase 
chromatography on a µBondapak phenyl column. The recovery of 
nalbuphine and naltrexone (internal standard) was greater than 90%. 
Calibration curves were linear over a concentration range of 3–36 ng/ml with 
coefficients of variation, within-day or between-day, not exceeding 8% at 
any level. Although the limit of detection was 0.3 ng/ml based on a signal-to-
noise ratio of 3, the reliable limit of quantitation was 1 ng/ml (coefficient of 
variation 12%) using 1 ml of plasma. The dual-electrode detector was 
operated in the screening mode of oxidation (electrode 1, 0.3 V and electrode 
2, 0.6 V), providing a greater specificity and reducing background noise. 
This procedure was applied to a large number of clinical samples in an 
intravenous dose-range pharmacokinetic study in patients.and dispersion.  
5. Mary Ann Quarrya, Reed C. Williamsa & Dolores S. Sebastiana A method 
for the determination of impurities and degradation products in nalbuphine 
hydrochloride injection by gradient elution high performance liquid 
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chromatography (HPLC) is reported. Reversed phase gradient elution 
chromatography was carried out using a mobile phase containing 0.05% 
trifluoroacetic acid, acetonitrile, and tetrahydrofuran. Validation data for 
linearity, accuracy, precision, robustness, detection limit, and quantitation 
limit are presented. The chromatographic system resolves nalbuphine from 
related substances with corrections made for differences in detector response 
at the specified wavelength. 
6. M. M. Fouad et.al., Three simple, sensitive and reproducible spectrometric 
methods for the selective determination of nalbuphine–HCl in presence of its 
oxidative degradate were investigated. The first method depended on the 
quantitative densitometric evaluation of thin layer chromatograms of the 
drug at 284 nm using chloroform–methanol–acetic acid (7:3:0.05 v/v/v) as a 
mobile phase, in a concentration range of 10-30 µg/spot. The second one 
used the pH induced difference absorbance (∆A) between 0.1M NaOH and 
0.1 M HCl drug solutions at 299 nm to determine 20-160 µg mL-1 of the 
drug. The third method was a bivariate calibration algorithm for the 
determination of nalbuphine–HCl over concentration range of 20-200 µg 
mL-1 . The proposed methods selectively analysed the drug in presence of up 
to 80% of its oxidative degradate with mean recoveries of 100.63±1.03 for 
densitometric method and up to 90% with recoveries of 99.97±1.16 and 
100.09±1.47% regarding the two other methods, respectively. The three 
proposed methods were successfully applied to analyse nalbuphine– HCl in 
its preparations, the results obtained were statistically analysed and found to 
be in accordance with those given by the compendial method. 
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AIM AND OBJECTIVE OF WORK 
The drug analysis plays an important role in the development of drugs, their 
manufacture and the therapeutic use. Pharmaceutical industries rely upon 
quantitative chemical analysis to ensure that the raw materials used and the final 
product obtained meets the required specification. The number of drugs and drug 
formulations introduced in to the market has been increasing at an alarming rate. 
These drugs or formulation may be either in the new entities in the market or partial 
structural modification of the existing drugs or novel dosage forms or multi 
component dosage forms. 
The multi component dosage form proves to be effective due to the combined mode 
of action on the body. The complexity of dosage forms including the presence of 
multiple drug entities posses considerable challenge to the analytical chemist during 
the development of assay procedure. The estimation of individual drugs in these 
multi component dosage forms becomes difficult due to cumbersome extraction or 
isolation procedures.  
For the present study of Nalbuphine HCl was selected. The extensive literature 
survey carried out and revealed that there is only few method reported for the 
estimation of this drug. Hence an attempt was made to develop a specific, precise, 
accurate, linear, simple, rapid, validated and cost effective RP-HPLC method for the 
estimation of this drug in Pharmaceutical dosage forms. 
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PLAN OF WORK 
To develop and validate an effective RP – HPLC method for the estimation of 
Nalbuphine HCl in bulk and its pharmaceutical dosage forms. 
So ,the plan of work for the designed study was as follows: 
• Gathering physical chemical properties of drug 
• From the UV- analysis ,selection of  λ max 
• Selection of chromatographic condition 
 Selection of stationary phase 
 Selection of  mobile phase  
 Selection of flow rate 
 Selection of Initial separation condition 
• Optimization of chromatographic condition 
• Validation of proposed method 
• Applying developed method to the marketed formulation. 
• Summarize methodology, finalize documentation.
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DRUG PROFILE 
Nalbuphine HCl 
Structure : 
 
Chemical name :  17-(cyclobutylmethyl)- 4,5α-epoxymorphinan-            
                                                    3, 6α, 14-triol hydrochloride 
Description : White to slightly off-white powder 
 
Molecular formula   : C21H27NO4·HCl  
Molecular mass        : 393.91 g/mol 
Bioavailability          : 81 % 
 
Half- life                     : 5 hours 
 
Category                     :    semi-synthetic opioid agonist-antagonist analgesic of  
                                          the phenanthrene series 
M.O.A  :     The exact mechanism of action is unknown, but is 
believed to interact with an opiate receptor site in the CNS (probably in or 
associated with the limbic system). The opiate antagonistic effect may result from 
competitive inhibition at the opiate receptor, but may also be a result of other 
mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a 
partial mu antagonist analgesic, with some binding to the delta receptor and minimal 
agonist activity at the sigma receptor.
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Adverse reaction :      • Cardiovascular: Hypertension, hypotension,  
                                              bradycardia, tachycardia, pulmonary edema.  
                                            •  Gastrointestinal: Cramps, dyspepsia, bitter taste.  
                                            •  Respiration: Depression, dyspnea, asthma.  
                                            •  Dermatological: Itching, burning, urticaria.  
                                            •  Obstetric: Pseudo-sinusoidal fetal heart rhythm. 
Dose   :  10 – 20mg 
 
Pharmacokinetics 
Mean plasma nalbuphine concentrations 5 min after intravenous administration of 
10 or 20 mg were 39 and 73 ng/ml, respectively. The mean maximum plasma 
concentrations (Cmax) after intramuscular or subcutaneous administration of 
nalbuphine 10 mg were 29 and 31 ng/ml, respectively. Mean Cmax values after 20 
mg doses were 60 and 56 ng/ml. Mean Cmax occurred 30 to 40 min after nalbuphine 
administration. The mean elimination half-lives of parenterally administered 
nalbuphine ranged between 2.2 and 2.6 h, regardless of dose given or route 
administered. The mean absolute bioavailability was 81% and 83% for the 10 and 20 
mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of 
subcutaneous nalbuphine. The mean volumes of distribution (Vss) of the 
intravenously administered drug were 290 and 274 l and the mean systemic 
clearances were 1.6 and 1.5 l/min following administration of 10 and 20 mg doses, 
respectively. Intramuscular and subcutaneous nalbuphine appear to be 
interchangeable based on the similarities in Cmax, mean times until maximum 
concentration, mean AUC data, and absolute bioavailabilities. 
Pharmacodynamics 
Nalbuphine is a synthetic opioid agonist-antagonist analgesic of the phenanthrene 
series. Nalbuphine's analgesic potency is essentially equivalent to that of morphine 
on a milligram basis. The opioid antagonist activity of nalbuphine is one-fourth as 
potent as nalorphine and 10 times that of pentazocine. Nalbuphine by itself has 
potent opioid antagonist activity at doses equal to or lower than its analgesic dose. 
When administered following or concurrent with mu agonist opioid analgesics (e.g., 
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morphine, oxymorphone, fentanyl), nalbuphine may partially reverse or block 
opioid-induced respiratory depression from the mu agonist analgesic. Nalbuphine 
may precipitate withdrawal in patients dependent on opioid drugs. Nalbuphine 
should be used with caution in patients who have been receiving mu opioid 
analgesics on a regular basis. 
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MATERIALS AND INSTRUMENTS 
Instruments used: 
 System              : HPLC Prominence Waters-2695 
 Pump                : I80 ( LC – 10 AT Vp series) 
 Detector            : UV/Visible E2469 
 Column             : Waters C 8 column. (150mm x 4.6 mm, 5 µ i.d.) 
 pH meter           : Elico 
 vacuum pump   : Gelman science 
 Digital balance  : Sartorious BSA224S-CW 
 Sonicator           : PCI Analytics 
Reagents and Chemicals 
Sodium Octane Sulphonate : AR grade 
Sodium Acetate Trihydrate : AR grade 
Glacial acetic acid  : AR grade 
Methanol   : AR grade 
Water                                      :         HPLC grade  
Reference Standards 
Nalbuphine hydrichloride      :     % purity 94.1 
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Preparation of solvents 
Preparation of buffer: 
Preparation of Buffer  
Dissolve 1.08 g sodium octane sulphonate and 23.8 g of sodium acetate trihydrate in 
550ml of water. 
Add 1.0ml triethylamine and 450 ml of methanol, and mix. Adjust with glacial 
acetic acid to a pH of 6.5±0.1. Filter and degas prior to use.  
Injection Brand Used: 
 ASMITHA TABLETS 
 Label claim:  
1.Nalbuphine HCl : 10 mg/mL  
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METHOD DEVELOPMENT AND OPTIMIZATION OF 
CHROMATOGRAPHIC CONDITIONS 
SOLUBILITY 
According to literature, Nalbuphine HCl soluble in soluble in Water (35.5 mg/mL at 
25ºC and Ethanol, insoluble in Chloroform and ether.  
SELECTION OF CHROMATOGRAPHIC CONDITION 
Proper selection of the method depends upon the nature of the sample (ionic / 
ionisable / neutral molecule), its molecular weight and solubility. The drugs selected 
in the present study are polar in nature and hence reversed phase or ion-pair or ion 
exchange chromatography method may be used. The reversed phase HPLC was 
selected for the separation because of its simplicity and suitability.  
SELECTION OF WAVELENGTH (λ max) 
In setting up the conditions for the development of the assay method, the choice of 
detection wavelength was based on the scanned absorption for Nalbuphine HCl. The 
spectrum was scanned over the range of 190 – 400 nm and was obtained by 
measuring the absorption of 1.0 mg/ml solution of Nalbuphine HCl in Water, 
prepared from stock solution. The spectrum was obtained by using 1cm quartz cell 
using water as reference solution. λ max of misoprstol was 280. Hence for estimation 
280 nm was selected.  
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Figure 6:    UV – spectrum of Nalbuphine HCl 
 
 7.1. METHOD DEVELOPMENT TRIALS 
Trial –1 
Prapration of solutions: 
 Mixed 0.05% trifluoroacetic acid, acetonitrile, and tetrahydrofuran 
 Preparataion of mobile phase: 
Mixed 350ml of 0.05% trifluoroacetic acid and 550 ml of acetonitrile and 100 ml of 
tetrahydrofuran shekwell and filtered through 0.45µ membrane filter degassed prior 
to use 
Mobile phase Composition : Isocratic 1.0ml/min       
 
Stationary Phase : Thermo Hypersil BDS C18, 250mm x 4.0mm, 5µm 
Mobile phase ratio               :35:55:10Trifluoroacetic acid:Methanol:Tetrahydrofuran 
Flow rate : 1.0 ml 
5.832 Nalbuphine Hydrochloride
223.5
285.1
AU
0.00
0.20
0.40
0.60
0.80
nm
200.00 250.00 300.00 350.00
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Column temperature : 250C 
Selected wave length : 280 nm. 
Injection Volume : 20 µl 
Run Time : 20 min. 
         
Result:  
While injecting the above chromatographic condition, nalbuphien HCl  RT was 
found identified separately.but it .     as found to be more noise in the base line and 
pH of the mobile phase also need to change. and RT of the compound is 1.976. 
Chromatogram 1 
 
Trial –2 
Preparation of Mobile Phase   
Dissolve 1.08 g sodium octane sulphonate and 23.8 g of sodium acetate trihydrate in 
550ml of water. 
Add  450 ml of methanol, and mix. Adjust with glacial acetic acid to a pH of 
6.5±0.1. Filter and degas prior to use.  
Mobile phase Composition : Isocratic 1.0ml/min       
 
Nalbuphine HCl - 1.976 
AU 
0.000 
0.002 
0.004 
0.006 
0.008 
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 
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Stationary Phase : Thermo Hypersil BDS C18, 250mm x 4.0mm, 
5µm Mobile phase ratio                : 55:45 Buffer:Methanol 
Flow rate : 1.0 ml 
Column temperature : 250C 
Selected wave length : 280 nm. 
Injection Volume : 20 µl 
Run Time : 20 min. 
Result:  
While injecting the above chromatographic condition, nalbuphien HCl  RT was 
found identified separately. But the tailing of the compound is 2.1. but as per the 
guidelines tailing more than 2.0 is not acceted. So tailing need to be minimize. 
 
Chromatogram 2 
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TRIAL - 3             
Preparation of Mobile Phase   
Dissolve 1.08 g sodium octane sulphonate and 47.2 g of sodium acetate trihydrate in 
550ml of water. 
Add  450 ml of methanol, and mix. Adjust with glacial acetic acid to a pH of 
6.5±0.1. Filter and degas prior to use.  
Mobile phase Composition : Isocratic 1.0ml/min       
 
Stationary Phase : Thermo Hypersil BDS C18, 250mm x 4.0mm, 
5µm Mobile phase ratio                :    55:45 Buffer:Methanol  
Flow rate : 1.0 ml 
Column temperature : 250C 
Selected wave length : 280 nm. 
Injection Volume : 20 µl 
Run Time : 20 min. 
Result:  
While injecting the above chromatographic condition, nalbuphien HCl  RT was 
found identified separately. But the tailing of the compound is 1.2. the response due 
to blank and placebo peak is high compare to the main peak. This should be 
minimize by changing the mobile phase. 
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TRIAL –4  
Stationary Phase : Thermo Hypersil BDS C18, 250mm x 4.0mm, 
5µm Mobile phase ratio  :       55:45 Buffer:Methanol 
Flow rate : 1.0 ml 
Column temperature : 250C 
Selected wave length : 280 nm. 
Injection Volume : 20 µl 
Run Time : 20 min. 
PREPARATION OF SOLUTIONS  
Preparation of Mobile Phase   
Dissolve 1.08 g sodium octane sulphonate and 23.8 g of sodium acetate trihydrate in 
550ml of water. 
Add 1.0ml triethylamine and 450 ml of methanol, and mix. Adjust with glacial 
acetic acid to a pH of 6.5±0.1. Filter and degas prior to use.  
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Chromatograms  4 
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OPTIMIZED CHROMATOGRAPHIC CONDITIONS: 
Stationary Phase : Thermo Hypersil BDS C18, 250mm x 4.0mm, 
5µm Mobile phase ratio  :       55:45 Buffer:Methanol 
Flow rate : 1.0 ml 
Column temperature : 250C 
Selected wave length : 280 nm. 
Injection Volume : 20 µl 
Run Time : 20 min. 
PREPARATION OF SOLUTIONS  
Preparation of Mobile Phase   
Dissolve 1.08 g sodium octane sulphonate and 23.8 g of sodium acetate trihydrate in 
550ml of water. 
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Add 1.0ml triethylamine and 450 ml of methanol, and mix. Adjust with glacial 
acetic acid to a pH of 6.5±0.1. Filter and degas prior to use.  
Diluent  
Mobile phase used as diluent 
Standard preparation 
Weigh accurately about 20 mg of Nalbuphine Hydrochloride working standard and 
transfer into a 100 ml volumetric flask, then add 70 ml of diluent, sonicate for 5 
minutes to dissolve and make up the volume with diluent.  
Sample preparation  
Select random of 20 Ampoules. Transfer the content into the 50 ml beaker. Pipette 
out 5 ml of  sample solution (equivalent to about 50 mg of Nalbuphine 
Hydrochloride), and transfer into a 250mL volumetric flask, add 170 mL of diluent, 
and make up the volume with diluent.  
Pipette out 5 ml of  solution, and transfer into a 250mL volumetric flask, add 170 
mL of diluent, and make up the volume with diluent.  
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VALIDATION OF RP-HPLC METHOD 
 After development of HPLC method for the estimation of the Single 
component dosage forms validation of the method was carried out. This section 
describes the procedure followed for the validation of the developed method. 
SYSTEM SUITABILITY STUDIES 
           System suitability studies were carried out as specified in the United States 
Pharmacopoeia (USP). These parameters include column efficiency, resolution, 
tailing factor and RSD were calculated in present study. 
System Suitability Parameters Observed value Acceptance criteria 
The Tailing factor for Nalbuphine Hydrochloride 
peak from first injection of standard preparation. 1.5 NMT 2.0 
Theoretical plate count for Nalbuphine 
Hydrochloride from first injection of standard 
preparation. 
3853 NLT 1500 
The % RSD of six replicate injections for Nalbuphine 
Hydrochloride of standard preparation.  0.1 NMT 2.0 
                             Table No: 1   System suitability parameters 
Specificity 
 The following methods were employed for demonstrating specificity for 
HPLC method. In the first method, the conditions of HPLC method developed, 
namely, percentage of the organic solvent in mobile phase, pH of the mobile phase, 
flow rate, etc. were changed in HPLC and the presence of additional peaks, if any, 
was observed. The second method involves the peak purity test method using diode 
array detector. The diode array derivative spectrums and derivative chromatograms 
of the standard and sample drug peaks were recorded and compared. The third 
method was based on measurement of the absorbance ratio of the drug peaks at 
different wavelengths. 
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Table No 2:    Specificity 
       Sample ID 
Interference 
Nalbuphine 
Hydrochloride RT 
Purity 
Angle  
Threshold 
angle 
Blank NIL NAP NAP 
Placebo NIL NAP NAP 
Standard+Placebo 6.123 0.15 0.304 
Standard  6.122 0.109 0.291 
Test Sample 6.123 0.15 0.304 
 
Accuracy  
Accuracy of the method was determined by recovery experiments. To the 
formulation, the reference standards of the respective drugs were added at the level 
of 100 %. These were further diluted by procedure as followed in estimation of 
formulation. The resulting sample solutions were analyzed by HPLC. The amount of 
the each drug present, percentage recovery, percentage relative standard deviation 
(% RSD) was calculated. The percentage recovery was calculated using the formula, 
 Percentage recovery 100][ x
b
aba −+
=
 
  Table No: 3   Recovery Studies
 
 
Series 
No of 
Sample 
Added in 
mg Found in mg Recovery in % 
Average 
in % 
50% 
01 26.65 26.35 98.9 
99.3 02 26.58 26.41 99.4 
03 26.42 26.35 99.7 
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75% 
01 39.52 39.79 100.7 
100.5 02 39.57 39.89 100.8 
03 39.66 39.70 100.1 
100% 
01 51.32 52.18 101.7 
101.2 02 51.63 52.15 101.0 
03 51.86 52.32 100.9 
 
125% 
01 65.16 65.51 100.5 
100.8 02 64.84 65.54 101.1 
03 65.08 65.65 100.9 
 
150% 
01 78.16 78.56 100.5 
100.7 02 77.80 78.54 100.9 
03 77.79 78.35 100.7 
 Mean 100.5 
 
Stdev. 0.72 
% RSD 0.7 
Confidence 
Interval 100.2 & 100.9  
 
Precision 
                Table No: 5 System Precision of Nalbuphine HCl 
No of injection RT Response 
01 6.600 2328333 
02 6.594 2329431 
03 6.596 2325802 
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04 6.594 2326325 
05 6.594 2323823 
06 6.592 2326956 
Mean 6.595 2326778 
SD 0.00 1968.65 
% RSD 0.0 0.1 
 
System Suitability Parameters Observed 
value 
Acceptance 
criteria 
The Tailing factor for Nalbuphine 
Hydrochloride peak from first injection of 
standard preparation. 
1.5 NMT 2.0 
Theoretical plate count for Nalbuphine 
Hydrochloride from first injection of 
standard preparation. 
3853 NLT 1500 
The % RSD of six replicate injections for 
Nalbuphine Hydrochloride of standard 
preparation.  
0.1 NMT 2.0 
The % RSD of Nalbuphine Hydrochloride 
peak RT for six injection of standard 
solution. 
0.0 NMT 1.0 
 
Test Preparation 
No. of Sample 
Method Precision 
Nalbuphine 
Hydrochloride 
01 99.3 
02 99.3 
03 99.5 
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04 99.7 
05 99.4 
06 99.5 
Mean 99.4 
SD 0.16 
% RSD 0.2 
 Confidence 
Interval 99.3 & 99.6 
 
Linearity and range 
                    Linearity was established by plotting a graph between concentration on 
X-axis and peak area on Y-axis and the correlation coefficient was determined. 
Seven different concentrations of Nalbuphine HCl concentration ranging from LOQ, 
50%, 75%, 100%, 125%, 150% and 200% with respect to working concentration 
were prepared and analyzed as per test method. The results are summarized in the 
table given below. 
S. No. % Level  Concentration in µg/ml (ppm) 
Peak Response of 
Nalbuphine Hydrochloride 
01 10% 20.00 226809 
02 25% 50.00 568281 
03 50% 100.00 1133345 
04 75% 150.00 1719578 
05 100% 200.00 2290890 
06 125% 250.00 2868422 
07 150% 300.00 3440805 
Slope 11494 
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Y intercept  -7149 
Coefficient of correlation  1.0000 
Coefficient of regression (r2) 1.0000 
Y intercept should be ±2.0% of the active 
response at 100% concentration -0.3 
 
 
 
Range  
Level Concentration in µg/ml 
%RSD 
Lower Level 10% 20.00 0.2 
Middle Level 100% 200.00 0.1 
Higher Level 150% 300.00 0.1 
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Ruggedness 
 Defined by the USP as the degree of reproducibility of results obtained under 
a variety of conditions, such as different laboratories, analysts, instruments, 
environmental conditions, operators and materials. Ruggedness is a measure of 
reproducibility of test results under normal, expected operational conditions from 
laboratory to laboratory and from analyst to analyst. 
Robustness  
In order to demonstrate the robustness of the method, the following 
optimized conditions were slightly varied. 
1. Effect of variation in Wavenlength variation 
2. Effect of variation in Column Oven Temperature 
The separation factor, retention times and peak symmetry were then calculated. 
1. Table No: 11      Effect of Wavelength  variation 
 
System Suitability 
Parameters 
Observed value at  
Wavelength 
 
Acceptance 
criteria 
 
278 nm 280 nm 282 nm 
The Tailing factor for Nalbuphine Hydrochloride 
peak from first injection of standard preparation. 1.5 1.5 1.5 NMT 2.0 
Theoretical plate count for Nalbuphine 
Hydrochloride from first injection of standard 
preparation. 
3677 3853 3603 NLT 1500 
The % RSD of six replicate injections for 
Nalbuphine Hydrochloride of standard preparation.  0.3 0.1 0.2 NMT 2.0 
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2. For Comparison between System -1 & System-2 
  
No. of Sample 
System -1 System-2 
Nalbuphine 
Hydrochloride 
Nalbuphine 
Hydrochloride 
01 99.3 99.6 
02 99.3 99.3 
03 99.5 99.1 
04 99.7 99.2 
05 99.4 99.1 
06 99.5 99.2 
Mean 99.4 99.2 
SD 0.16 0.19 
% RSD 0.2 0.2 
 Confidence Interval 99.3 & 99.6 99.1 & 99.4 
 
18.2 Effect of variation in Column Oven Temperature 
To demonstrate the robustness of test method, check the system suitability 
parameters by injecting standard preparations into the HPLC system at 35°C and at 
45°C of Column oven temperature. Evaluate the system suitability parameters and 
tabulate the results in the table given below. 
Table no: 12 
 
System Suitability 
Parameters 
Observed value with Column 
Oven Temperature 
 
Acceptance 
criteria 
 
20°C 25°C 30°C 
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The Tailing factor for Nalbuphine Hydrochloride 
peak from first injection of standard preparation. 1.6 1.5 1.6 NMT 2.0 
Theoretical plate count for Nalbuphine 
Hydrochloride from first injection of standard 
preparation. 
3079 3853 3509 NLT 1500 
The % RSD of six replicate injections for 
Nalbuphine Hydrochloride of standard preparation.  0.1 0.1 0.1 NMT 2.0 
 
Stability studies: 
 Stability of the sample and standard used in HPLC method is required  
for a reasonable time to reproducible and reliable results. The stability of the sample 
spiked with the drug was subjected to short term stability at room temperature after 
8 hours. 
Table No: 15   Refrigerator Solution Stability      
Time in hours Standard area Sample area 
Initial 2399731 2378739 
4th Hours 2409544 2378739 
8th Hours 2401025 2374541 
12th Hours 2405911 2381950 
16th Hours 2412544 2388625 
20th Hours 2414694 2385761 
24th Hours 2415554 2380472 
28th Hours 2423670 2392169 
32nd Hours 2426932 2393142 
36th Hours 2412867 2388382 
40th Hours 2422432 2390247 
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44th Hours 2417133 2394083 
48th Hours 2406559 2384841 
Mean 2412969 2385515 
SD 8400.2 6238.7 
% RSD 0.3 0.3 
 
17.4 Filter Validation 
Carry out filter validation using three different filters namely, 0.45 µm nylon, 
0.45 µm PVDF and whatman No.1 compare with unfilter sample. Prepare the 
standard solution as per the test methods and similarly prepare the test 
preparation.  
Filter the test preparation through individual filters. Inject standard solution and 
filtered test solution into the HPLC system under the chromatographic condition. 
Calculate the % difference between the assay obtained in different filters.   
Filter description 
Filters 
0.45µm Nylon 0.45 µm PVDF Whatman No.1 
Manufacturer 
Name 
Nupore Filtration 
Systems Pvt. Ltd. Millipore  GE Healthcare Ltd 
Lot No. QNN 0939314 R3PA17924 1001-150 
Size 0.45µm 0.45µm 1 
 
Filters Assay in % Difference from Initial 
Unfilter 99.7 NAP 
0.45 µm nylon 98.2 1.5 
0.45 µm PVDF 99.7 0.0 
Whatman No.1 100.4 0.7 
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ASSAY OF PROPOSED METHOD: 
Procedure:   
Separately inject both the standard and sample preparations  into liquid 
chromatogram and record the peak area responses.  The % RSD is not more than 
2.0. 
a) Correlation Coefficient (r):   
[ ] ) )((( )2222 yynxxn
yxxyn
∑−∑∑−∑
∑∑−∑
 
Σ   = Sum of, x = Conc. of the Component, y= Average area of component, 
n  = number of observations 
 b) Slope (a) = 
∑ ∑−
∑ ∑ ∑−
))X(Xn(
)YXXYn(
22    
c) The equation of straight line: Y = a X + b   
d) Intercept on the Y axis (b) = Y - a X ,    ( X  = mean values of X,) 
     (Y  = Mean values of Y) 
e) Calculation 
Calculate the mg of Nalbuphine Hydrochloride in the injection: 
Ru X Ws X 250 X P X 1 
------------------------------- 
Rs X 100 X V X 100  
=Content in mg/ml 
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Calculate the Nalbuphine Hydrochloride content in percentage of the label claim: 
     Content in mg 
= ----------------------X 100 
          Label claim 
Where,   
Ru= Peak response for Nalbuphine Hydrochloride from the sample solution 
Rs= Peak response for Nalbuphine Hydrochloride from the standard solution 
Ws=Standard weight 
V= 5 ml of the sample  
P=Purity in as such basis. 
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8. CHROMATOGRAMS 
Chromatogram No`:1  
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Chromatogram No: 3   
PLACEBO NALBUPHINE HCL  
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A Representative chromatogram of the linearity 10%-150% solution 
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High flow 
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RESULT AND DISCUSSION 
VALIDATION OF THE METHOD 
The suitability of the system was studied by the values obtained for 
Theoretical plate, Resolution and tailing factor, %RSD of the chromatogram of 
standard drugs and presented in the table(1). The selectivity of the method was 
revealed by the repeated injection of mobile phase and no interference was found 
and presented in Table (2) 
The accuracy of the method was determined by recovery experiments. The 
recovery studies were carried out by preparing 3 individual samples with same 
procedure from the formulation and injecting. The percentage recovery and 
percentage relative standard deviation of the percentage recovery was calculated and 
presented in Tables (3) & (4). From the data obtained, added of standard drugs were 
found to be accurate. 
The precision of the method was demonstrated by system and method 
precision. All solutions were injected into the chromatographic system. The peak 
area and percentage relative standard deviation were calculated and presented in 
tables (5) & (6). 
The linearity of proposed method were performed by using the concentration 
range of 10 % to 150 % of standard concentration i.e 20 µg/ml to 200 µg/ml of 
Nalbuphine HCl was presented in Table 7, 8 , 9& 10 .The response factor, slope, 
intercept and correlation co-efficient were calculated. The slope, intercept, 
correlation co-efficient were found to be 11497, 7149, 1.0000. The calibration 
curves were plotted using response factor (Vs) concentration of standard solutions 
(fig: 6 &7). The calibration graph shows that linear response was obtained over the 
range of concentration used in the procedure. These data demonstrates that the 
method have adequate sensitivity to the analytes. The range demonstrate that the 
method is linear outside the limits of expected use. 
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The robustness of the method was studied by carrying out experiments by 
changing conditions discussed earlier. The response factors for these changed 
chromatographic parameters were almost same as that of the fixed chromatographic 
parameters (table11&12) and hence developed method is said to be robust and 
ruggedness performed   by analyst 1 and analyst 2 . 
The stability studies were carried out at zero hour and after 48 hour, results 
were tabulated in table 15. 
VALIDATION PROTOCOL SUMMARY 
The following is the summary of Analytical method validation study conducted for 
Assay of Nalbuphine Hydrochloride in Nalbuphine injection 10 mg/mL. 
  System Suitability and System Precision is established as mentioned in the test 
method. 
  The test method is specific for the estimation of Nalbuphine Hydrochloride in 
Nalbuphine injection 10 mg/mL. 
  There is no interference or co-elution of degradants in quantifying the 
Nalbuphine Hydrochloride in Nalbuphine injection 10 mg/mL. 
  There test method is meeting Method Precision and Intermediate Precision 
acceptance criteria. 
 The method performance at lower to higher levels (10 % to 150%) is Linear, 
Precise and Accurate. 
 The detector response is linear with a coefficient of correlation 1.0000 and 
coefficient of regression (r2) 1.0000 for Nalbuphine Hydrochloride. 
 Range is found within the limit. 
 The method is found Linear, Precise and Accurate. 
  The test method is rugged for system to system, analyst to analyst. 
  The standard solutions and test solution was stable at bench top for a period of 48 
hours. 
 The allowable variation in column temperature is from 20°C to 30°C. 
 The allowable variation in Flow Rate is from 0.8 ml/min to 1.2 ml/min. 
 The allowable variation in Wavelength Change is from 278 nm to 282 nm. 
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 The Unfilter, 0.45 µ Nylon and 0.45 µ PVDF, Whatman No.1 are suitable for 
performing filtration. 
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SUMMARY AND CONCLUSION 
From the reported literature, there were few methods established for the 
determination of Nalbuphine HCl. 
It was concluded that there was few method reported for the estimation of the 
above selected component dosage form, which promote to pursue the present work. 
The scope and object of the present work is to develop and validate a new simple 
HPLC method for estimation of Nalbuphine HCl in injection dosage form. 
  In RP-HPLC method development, the estimation was carried out by using 
the Thermo Hypertsil C 18 column (4.6 X 250 mm) with 5-micron particle size. 
Injection volume of 50µl is injected and eluted with the mobile phase Sodium 
Acetate Buffer, Methanol with the ratio of 55: 45, which is pumped at the flow rate 
of 1.0 ml / min. Detection was carried out at 280 nm. Quantitation was done by 
calibration curve method with the above mentioned optimized chromatographic 
condition. This system produced symmetric peak shape, good resolution and 
reasonable retention times of Nalbuphine HCl were found to be 6.109 minutes. 
 The 20 µg/ml to 200 µg/ml of Nalbuphine HCl. The slope intercept and 
correlation coefficient(s) were found to be, 11497, 7149, 1.0000 for Nalbuphine HCl 
which indicates excellent correlation factor Vs concentration of standard solutions. 
Precision of the developed methods was studied under system precision, 
method precision. The %RSD values for precision was found to be within the 
acceptable limit, which revealed that the developed method was precise. The 
developed method was found to be robust. The %RSD values for recovery 
percentage of Nalbuphine HCl was found to be within the acceptable criteria. The 
result indicates satisfactory accuracy of method for estimation of the above 
mentioned drugs. 
Hence, the chromatographic method developed for Nalbuphine HCl are 
rapid, simple, specific, sensitive, precise, Accurate. The RP-HPLC was simple and 
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does not suffer from common excipients in pharmaceutical preparation and highly 
useful in the analysis of drugs in pharmaceutical formulation.   
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